S&P 500

5.477,90

0,16%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
Reino Unido
LSE
Basilea Pharmaceutica Ag (0QNA)
Basilea Pharmaceutica Ag (0QNA) Notícias

0QNA

Basilea Pharmaceutica (0QNA)

Basilea Pharmaceutica Ag

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0QNA

1

Data	Hora	Fonte	Título	Código	Companhia
20/06/2024	02:15	UK Regulatory	Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation	LSE:0QNA	Basilea Pharmaceutica Ag
20/06/2024	02:15	UK Regulatory	Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation	LSE:0QNA	Basilea Pharmaceutica Ag
16/05/2024	02:15	UK Regulatory	Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	LSE:0QNA	Basilea Pharmaceutica Ag
16/05/2024	02:15	UK Regulatory	Starke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus	LSE:0QNA	Basilea Pharmaceutica Ag
03/05/2024	02:15	UK Regulatory	Basilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024	LSE:0QNA	Basilea Pharmaceutica Ag
03/05/2024	02:15	UK Regulatory	Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024	LSE:0QNA	Basilea Pharmaceutica Ag
24/04/2024	13:00	UK Regulatory	Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des Verwaltungsrats	LSE:0QNA	Basilea Pharmaceutica Ag
24/04/2024	13:00	UK Regulatory	Basilea shareholders approve all proposals of the board of directors at the annual general meeting	LSE:0QNA	Basilea Pharmaceutica Ag
09/04/2024	02:15	UK Regulatory	Basilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-Wirkstoffklasse	LSE:0QNA	Basilea Pharmaceutica Ag
09/04/2024	02:15	UK Regulatory	Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics	LSE:0QNA	Basilea Pharmaceutica Ag
04/04/2024	02:15	UK Regulatory	Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications	LSE:0QNA	Basilea Pharmaceutica Ag
04/04/2024	02:15	UK Regulatory	Basilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekannt	LSE:0QNA	Basilea Pharmaceutica Ag
11/03/2024	03:15	UK Regulatory	Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	LSE:0QNA	Basilea Pharmaceutica Ag
11/03/2024	03:15	UK Regulatory	Anhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus	LSE:0QNA	Basilea Pharmaceutica Ag
13/02/2024	03:15	UK Regulatory	Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	LSE:0QNA	Basilea Pharmaceutica Ag
13/02/2024	03:15	UK Regulatory	Basilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-Portfolio	LSE:0QNA	Basilea Pharmaceutica Ag